Capricor Therapeutics Stock Price - CAPR

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 2.77 ▲ 0.06 (2.21%)
Company Name Stock Ticker Symbol Market Type
Capricor Therapeutics Inc CAPR NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.04 1.50% 2.71 2.81 2.59 2.65 2.67 19:59:48
Bid Price Ask Price Spread Spread % News
2.51 3.65 1.14 31.23% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
304 63,600 $ 2.71 $ 172,652 1,568,802 0.2526 - 8.85
Last Trade Time Type Quantity Stock Price Currency
17:45:55 formt 200 $ 2.77 USD

Capricor Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 10.12M 3.74M $ -15.19M -5.32 - 58.46k
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Capricor Therapeutics News

Loading Messages....

Latest CAPR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CAPR Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week2.833.162.52.8389204k-0.12-4.24%
1 Month5.
3 Months0.29558.850.2745.6611858k2.4145817.09%
6 Months0.42958.850.25264.4470525k2.2805530.97%
1 Year1.098.850.25263.3541371k1.62148.62%
3 Years3.598.850.25262.3070528k-0.88-24.51%
5 Years4.3510.680.25262.3913329k-1.64-37.70%

Capricor Therapeutics Description

Capricor Therapeutics Inc is a United State-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.

Your Recent History
Capricor T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.